Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease

Current Opinion in Pharmacology

Volumn 26, Issue , 2016, Pages 87-95

  Olson, Katherine E ^a   Gendelman, Howard E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ANTIPARKINSON AGENT; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PD 01; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PRX 002; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RESVERATROL; SILYMARIN; TANSHINONE; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; IMMUNOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; IMMUNOMODULATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; T-LYMPHOCYTES, REGULATORY;

EID: 84946606692     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.10.006     Document Type: Review

References (79)

1. C.W. Olanow, M.B. Stern, and K. Sethi The scientific and clinical basis for the treatment of Parkinson disease (2009) Neurology 72 2009 S1 S136
2. R.L. Mosley, J.A. Hutter-Saunders, D.K. Stone, and H.E. Gendelman Inflammation and adaptive immunity in Parkinson's disease Cold Spring Harb Perspect Med 2 2012 a009381
3. K.M. Anderson, K.E. Olson, K.A. Estes, K. Flanagan, H.E. Gendelman, and R.L. Mosley Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders Transl Neurodegener 3 2014 25
4. B. Liu, and J.S. Hong Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention J Pharmacol Exp Ther 304 2003 1 7
5. H. Chen, E.J. O'Reilly, M.A. Schwarzschild, and A. Ascherio Peripheral inflammatory biomarkers and risk of Parkinson's disease Am J Epidemiol 167 2008 90 95
6. M. Mogi, M. Harada, H. Narabayashi, H. Inagaki, M. Minami, and T. Nagatsu Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease Neurosci Lett 211 1996 13 16
7. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients Neurosci Lett 165 1994 208 210
8. S. Hunot, B. Brugg, D. Ricard, P.P. Michel, M.P. Muriel, M. Ruberg, B.A. Faucheux, Y. Agid, and E.C. Hirsch Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease Proc Natl Acad Sci U S A 94 1997 7531 7536
9. U.K. Hanisch, and H. Kettenmann Microglia: active sensor and versatile effector cells in the normal and pathologic brain Nat Neurosci 10 2007 1387 1394
10. C.A. Colton Heterogeneity of microglial activation in the innate immune response in the brain J Neuroimmune Pharmacol 4 2009 399 418
11. V. Brochard, B. Combadiere, A. Prigent, Y. Laouar, A. Perrin, V. Beray-Berthat, O. Bonduelle, D. Alvarez-Fischer, J. Callebert, J.M. Launay, and et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease J Clin Invest 119 2009 182 192
12. P.L. McGeer, S. Itagaki, B.E. Boyes, and E.G. McGeer Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 38 1988 1285 1291
13. I. Kurkowska-Jastrzebska, A. Wronska, M. Kohutnicka, A. Czlonkowski, and A. Czlonkowska MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease Acta Neurobiol Exp (Wars) 59 1999 1 8
14. A.D. Reynolds, D.K. Stone, J.A. Hutter, E.J. Benner, R.L. Mosley, and H.E. Gendelman Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease J Immunol 184 2010 2261 2271
15. A.D. Reynolds, R. Banerjee, J. Liu, H.E. Gendelman, and R.L. Mosley Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease J Leukoc Biol 82 2007 1083 1094
16. J.A. Saunders, K.A. Estes, L.M. Kosloski, H.E. Allen, K.M. Dempsey, D.R. Torres-Russotto, J.L. Meza, P.M. Santamaria, J.M. Bertoni, D.L. Murman, and et al. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease J Neuroimmune Pharmacol 7 2012 927 938
17. K. Rees, R. Stowe, S. Patel, N. Ives, K. Breen, C.E. Clarke, and Y. Ben-Shlomo Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies Cochrane Database Syst Rev 2011 CD008454
18. Y. Du, Z. Ma, S. Lin, R.C. Dodel, F. Gao, K.R. Bales, L.C. Triarhou, E. Chernet, K.W. Perry, D.L. Nelson, and et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Proc Natl Acad Sci U S A 98 2001 14669 14674
19. Y. He, S. Appel, and W. Le Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum Brain Res 909 2001 187 193
20. H.S. Kim, and Y.H. Suh Minocycline and neurodegenerative diseases Behav Brain Res 196 2009 168 179
21. L. Lu, F. Li, and X. Wang Novel anti-inflammatory and neuroprotective agents for Parkinson's disease CNS Neurol Disord Drug Targets 9 2010 232 240
22. T. Tikka, B.L. Fiebich, G. Goldsteins, R. Keinanen, and J. Koistinaho Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia J Neurosci 21 2001 2580 2588
23. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease Neurology 66 2006 664 671
24. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results Clin Neuropharmacol 31 2008 141 150
25. R. Dodel, A. Spottke, A. Gerhard, A. Reuss, S. Reinecker, N. Schimke, C. Trenkwalder, F. Sixel-Doring, B. Herting, C. Kamm, and et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial) Mov Disord 25 2010 97 107
26. T.K. Lin, S.D. Chen, Y.C. Chuang, H.Y. Lin, C.R. Huang, J.H. Chuang, P.W. Wang, S.T. Huang, M.M. Tiao, J.B. Chen, and et al. Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy Int J Mol Sci 15 2014 1625 1646
27. D.D. Lofrumento, G. Nicolardi, A. Cianciulli, F. De Nuccio, V. La Pesa, V. Carofiglio, T. Dragone, R. Calvello, and M.A. Panaro Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses Innate Immun 20 2014 249 260
28. F. Zhang, J.S. Shi, H. Zhou, B. Wilson, J.S. Hong, and H.M. Gao Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions Mol Pharmacol 78 2010 466 477
29. B. Ren, Y.X. Zhang, H.X. Zhou, F.W. Sun, Z.F. Zhang, Z. Wei, C.Y. Zhang, and D.W. Si Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease J Neurol Sci 348 2015 142 152
30. S. Wang, H. Jing, H. Yang, Z. Liu, H. Guo, L. Chai, and L. Hu Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease J Ethnopharmacol 164 2015 247 255
31. A. Borah, R. Paul, S. Choudhury, A. Choudhury, B. Bhuyan, A. Das Talukdar, M. Dutta Choudhury, and K.P. Mohanakumar Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action CNS Neurosci Ther 19 2013 847 853
32. M. Geed, D. Garabadu, A. Ahmad, and S. Krishnamurthy Silibinin pretreatment attenuates biochemical and behavioral changes induced by intrastriatal MPP+ injection in rats Pharmacol Biochem Behav 117 2014 92 103
33. R. Haddadi, A.M. Nayebi, S. Farajniya, S.E. Brooshghalan, and H. Sharifi Silymarin improved 6-OHDA-induced motor impairment in hemi-parkisonian rats: behavioral and molecular study Daru 22 2014 38
34. U.J. Jung, M.T. Jeon, M.S. Choi, and S.R. Kim Silibinin attenuates MPP(+)-induced neurotoxicity in the substantia nigra in vivo J Med Food 17 2014 599 605
35. Y. Lee, H.R. Park, H.J. Chun, and J. Lee Silibinin prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease via mitochondrial stabilization J Neurosci Res 93 2015 755 765
36. Y. Tian, Y. Zhang, R. Zhang, S. Qiao, and J. Fan Resolvin D2 recovers neural injury by suppressing inflammatory mediators expression in lipopolysaccharide-induced Parkinson's disease rat model Biochem Biophys Res Commun 460 2015 799 805
37. S.J. Chinta, A. Ganesan, P. Reis-Rodrigues, G.J. Lithgow, and J.K. Andersen Anti-inflammatory role of the isoflavone diadzein in lipopolysaccharide-stimulated microglia: implications for Parkinson's disease Neurotox Res 23 2013 145 153
38. A. Ghosh, A. Kanthasamy, J. Joseph, V. Anantharam, P. Srivastava, B.P. Dranka, B. Kalyanaraman, and A.G. Kanthasamy Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease J Neuroinflamm 9 2012 241
39. B.A. t Hart, S. Copray, and I. Philippens Apocynin, a low molecular oral treatment for neurodegenerative disease Biomed Res Int 2014 2014 298020
40. A. Pisanu, D. Lecca, G. Mulas, J. Wardas, G. Simbula, S. Spiga, and A.R. Carta Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-gamma agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease Neurobiol Dis 71 2014 280 291
41. A.R. Carta, and A. Pisanu Modulating microglia activity with PPAR-gamma agonists: a promising therapy for Parkinson's disease? Neurotox Res 23 2013 112 123
42. P. Garrido-Gil, B. Joglar, A.I. Rodriguez-Perez, M.J. Guerra, and J.L. Labandeira-Garcia Involvement of PPAR-gamma in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease J Neuroinflamm 9 2012 38
43. J.K. Barbiero, R. Santiago, F.S. Tonin, S. Boschen, L.M. da Silva, M.F. Werner, C. da Cunha, M.M. Lima, and M.A. Vital PPAR-alpha agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease Prog Neuropsychopharmacol Biol Psychiatry 53 2014 35 44
44. J.K. Barbiero, R.M. Santiago, D.S. Persike, M.J. da Silva Fernandes, F.S. Tonin, C. da Cunha, S. Lucio Boschen, M.M. Lima, and M.A. Vital Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine Behav Brain Res 274 2014 390 399
45. D. Lecca, D.K. Nevin, G. Mulas, M.A. Casu, A. Diana, D. Rossi, G. Sacchetti, and A.R. Carta Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARgamma agonist in vitro and in MPTP-treated mice Neuroscience 2015
46. C.R. Swanson, V. Joers, V. Bondarenko, K. Brunner, H.A. Simmons, T.E. Ziegler, J.W. Kemnitz, J.A. Johnson, and M.E. Emborg The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys J Neuroinflamm 8 2011 91
47. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial Lancet Neurol 14 2015 795 803 10.1016/S1474-4422(15)00144-1
48. D.K. Simon, T. Simuni, J. Elm, J. Clark-Matott, A.K. Graebner, L. Baker, S.R. Dunlop, M. Emborg, C. Kamp, J.C. Morgan, and et al. Peripheral biomarkers of Parkinson's disease progression and pioglitazone effects J Parkinsons Dis 2015 [Epub ahead of print]
49. M. Shahaduzzaman, K. Nash, C. Hudson, M. Sharif, B. Grimmig, X. Lin, G. Bai, H. Liu, K.E. Ugen, C. Cao, and et al. Anti-human alpha-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-alpha-synuclein rat model of Parkinson's disease PLoS One 10 2015 e0116841
50. D. Games, E. Valera, B. Spencer, E. Rockenstein, M. Mante, A. Adame, C. Patrick, K. Ubhi, S. Nuber, P. Sacayon, and et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models J Neurosci 34 2014 9441 9454
51. V. Lindstrom, T. Fagerqvist, E. Nordstrom, F. Eriksson, A. Lord, S. Tucker, J. Andersson, M. Johannesson, H. Schell, P.J. Kahle, and et al. Immunotherapy targeting alpha-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] alpha-synuclein mice Neurobiol Dis 69 2014 134 143
52. T. Fagerqvist, V. Lindstrom, E. Nordstrom, A. Lord, S.M. Tucker, X. Su, C. Sahlin, A. Kasrayan, J. Andersson, H. Welander, and et al. Monoclonal antibodies selective for alpha-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation J Neurochem 126 2013 131 144
53. H.T. Tran, C.H. Chung, M. Iba, B. Zhang, J.Q. Trojanowski, K.C. Luk, and Lee VM: Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration Cell Rep 7 2014 2054 2065
54. N.N. Vaikath, N.K. Majbour, K.E. Paleologou, M.T. Ardah, E. van Dam, W.D. van de Berg, S.L. Forrest, L. Parkkinen, W.P. Gai, N. Hattori, and et al. Generation and characterization of novel conformation-specific monoclonal antibodies for alpha-synuclein pathology Neurobiol Dis 79 2015 81 99
55. V. Sanchez-Guajardo, A. Annibali, P.H. Jensen, and M. Romero-Ramos alpha-Synuclein vaccination prevents the accumulation of parkinson disease-like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model J Neuropathol Exp Neurol 72 2013 624 645
56. M. Mandler, E. Valera, E. Rockenstein, H. Weninger, C. Patrick, A. Adame, R. Santic, S. Meindl, B. Vigl, O. Smrzka, and et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials Acta Neuropathol 127 2014 861 879
57. A. Schneeberger, M. Mandler, F. Mattner, and W. Schmidt Vaccination for Parkinson's disease Parkinsonism Relat Disord 18 Suppl 1: 2012 S11 S13
58. M. Mandler, E. Valera, E. Rockenstein, M. Mante, H. Weninger, C. Patrick, A. Adame, S. Schmidhuber, R. Santic, A. Schneeberger, and et al. Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy Mol Neurodegener 10 2015 10
59. J.M. Orgogozo, S. Gilman, J.F. Dartigues, B. Laurent, M. Puel, L.C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, and et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization Neurology 61 2003 46 54
60. A.D. Reynolds, I. Kadiu, S.K. Garg, J.G. Glanzer, T. Nordgren, P. Ciborowski, R. Banerjee, and H.E. Gendelman Nitrated alpha-synuclein and microglial neuroregulatory activities J Neuroimmune Pharmacol 3 2008 59 74
61. E.J. Benner, R.L. Mosley, C.J. Destache, T.B. Lewis, V. Jackson-Lewis, S. Gorantla, C. Nemachek, S.R. Green, S. Przedborski, and H.E. Gendelman Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease Proc Natl Acad Sci U S A 101 2004 9435 9440
62. L.M. Kosloski, E.A. Kosmacek, K.E. Olson, R.L. Mosley, and H.E. Gendelman GM-CSF induces neuroprotective and anti-inflammatory responses in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxicated mice J Neuroimmunol 265 2013 1 10
63. Q. Lan, H. Fan, V. Quesniaux, B. Ryffel, Z. Liu, and S.G. Zheng Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases? J Mol Cell Biol 4 2012 22 28
64. D.E. Lowther, and D.A. Hafler Regulatory T cells in the central nervous system Immunol Rev 248 2012 156 169
65. J.D. Cherry, J.A. Olschowka, and M.K. O'Banion Are "resting" microglia more "m2"? Front Immunol 5 2014 594
66. K.Y. Shivers, A. Nikolopoulou, S.I. Machlovi, S. Vallabhajosula, and M.E. Figueiredo-Pereira PACAP27 prevents Parkinson-like neuronal loss and motor deficits but not microglia activation induced by prostaglandin J2 Biochim Biophys Acta 1842 2014 1707 1719
67. M. Delgado, and D. Ganea Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions Amino Acids 45 2013 25 39
68. L. Fraccaroli, E. Grasso, V. Hauk, D. Paparini, E. Soczewski, G. Mor, C. Perez Leiros, and R. Ramhorst VIP boosts regulatory T cell induction by trophoblast cells in an in vitro model of trophoblast-maternal leukocyte interaction J Leukoc Biol 98 2015 49 58
69. J.A. Waschek VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair Br J Pharmacol 169 2013 512 523
70. M.L. Kelso, B.R. Elliott, N.A. Haverland, R.L. Mosley, and H.E. Gendelman Granulocyte-macrophage colony stimulating factor exerts protective and immunomodulatory effects in cortical trauma J Neuroimmunol 278 2015 162 173
71. W.R. Schabitz, C. Kruger, C. Pitzer, D. Weber, R. Laage, N. Gassler, J. Aronowski, W. Mier, F. Kirsch, T. Dittgen, and et al. A neuroprotective function for the hematopoietic protein granulocyte-macrophage colony stimulating factor (GM-CSF) J Cereb Blood Flow Metab 28 2008 29 43
72. G. Lacan, H. Dang, B. Middleton, M.A. Horwitz, J. Tian, W.P. Melega, and D.L. Kaufman Bacillus Calmette-Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease J Neurosci Res 91 2013 1292 1302
73. M.K. Schuhmann, P. Kraft, G. Stoll, K. Lorenz, S.G. Meuth, H. Wiendl, B. Nieswandt, T. Sparwasser, N. Beyersdorf, T. Kerkau, and et al. CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke J Cereb Blood Flow Metab 35 2015 6 10
74. S.Y. Na, E. Mracsko, A. Liesz, T. Hunig, and R. Veltkamp Amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice Stroke 46 2015 212 220
75. A. Chan, J. Yan, P. Csurhes, J. Greer, and P. McCombe Circulating brain derived neurotrophic factor (BDNF) and frequency of BDNF positive T cells in peripheral blood in human ischemic stroke: effect on outcome J Neuroimmunol 286 2015 42 47
76. W. Zhao, D.R. Beers, B. Liao, J.S. Henkel, and S.H. Appel Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms Neurobiol Dis 48 2012 418 428
77. D.R. Beers, J.S. Henkel, W. Zhao, J. Wang, A. Huang, S. Wen, B. Liao, and S.H. Appel Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis Brain 134 2011 1293 1314
78. J.S. Henkel, D.R. Beers, S. Wen, A.L. Rivera, K.M. Toennis, J.E. Appel, W. Zhao, D.H. Moore, S.Z. Powell, and S.H. Appel Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival EMBO Mol Med 5 2013 64 79
79. E.S. Chung, G. Lee, C. Lee, M. Ye, H.S. Chung, H. Kim, S.S. Bae, D.S. Hwang, and H. Bae Bee venom phospholipase A2, a novel Foxp3+ regulatory T cell inducer, protects dopaminergic neurons by modulating neuroinflammatory responses in a mouse model of Parkinson's Disease J Immunol 2015 pii: 1500386. [Epub ahead of print]